An important part of managing pulmonary arterial hypertension is working with a specialist who understands this rare and ...
An adult patient with pulmonary arterial hypertension (PAH) and metastatic lung adenocarcinoma showed significant clinical improvement when chemotherapy and immunotherapy were added to PAH triple ...
Prescribing the biologic drug sotatercept alongside standard treatment for the most severe form of pulmonary hypertension significantly reduces the likelihood of worsening disease when added within ...
MANCHESTER, England — Use of immunosuppressive drugs within 5 years of the onset of systemic sclerosis (SSc) did not lower patients’ risk for developing pulmonary arterial hypertension (PAH) but was ...
New findings reveal pulmonary arterial hypertension may affect the brain early. Learn how inflammation and cognitive decline ...
A new phase 3 study comparing mono and duo therapies may yield greater guidance and treatment options for children with pulmonary arterial hypertension (PAH). PAH is a rare condition in children, but ...
Merck MRK announced that the phase III HYPERION study evaluating its pulmonary arterial hypertension (“PAH”) drug, Winrevair (sotatercept), in newly diagnosed intermediate or high-risk PAH patients, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results